Abstract

INTRODUCTION: The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD).

METHODS AND ANALYSIS: The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment.

ETHICS AND DISSEMINATION: All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals.

CONCLUSION: This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.

Rights

Copyright information: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/'>https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/'>https://creativecommons.org/licenses/by/4.0/.

Cite as

Wild, J., Porter, J., Molyneaux, P., George, P., Stewart, I., Allen, R., Aul, R., Baillie, J., Barratt, S., Beirne, P., Bianchi, S., Blaikley, J., Brooke, J., Chaudhuri, N., Collier, G., Denneny, E., Docherty, A., Fabbri, L., Gibbons, M., Gleeson, F., Gooptu, B., Hall, I., Hanley, N., Heightman, M., Hillman, T., Johnson, S., Jones, M., Khan, F., Lawson, R., Mehta, P., Mitchell, J., Platé, M., Poinasamy, K., Quint, J., Rivera-Ortega, P., Semple, M., Simpson, A., Smith, D., Spears, M., Spencer, L., Stanel, S., Thickett, D., Thompson, A., Walsh, S., Weatherley, N., Weeks, M., Wootton, D., Brightling, C., Chambers, R., Ho, L., Jacob, J., Piper Hanley, K., Wain, L. & Jenkins, R. 2021, 'Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)', BMJ Open Respiratory Research, 8(1), article no: e001049. http://dx.doi.org/10.1136/bmjresp-2021-001049

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 16 June 2022
Was this page helpful?